1. Search Result
Search Result
Results for "

HAT inhibitor

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

5

Natural
Products

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15887
    MG 149
    10+ Cited Publications

    Tip60 HAT inhibitor

    Histone Acetyltransferase Epigenetic Reader Domain Apoptosis Cancer
    MG149 (Tip60 HAT inhibitor) is a selective and potent Tip60 inhibitor with IC50 of 74 uM, similar potentcy for MOF (IC50= 47 uM); little potent for PCAF and p300 (IC50 >200 uM) .
    MG 149
  • HY-120290

    Histone Acetyltransferase Cancer
    PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and p300. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity .
    PU141
  • HY-154944

    Histone Acetyltransferase Cancer
    JG-2016 is a potent inhibitor of histone acetyltransferase 1 (HAT1), with an IC50 of 14.8 μM in the HAT1 acetylation assays .
    JG-2016
  • HY-136285

    Histone Acetyltransferase Cancer
    CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
    CPI-1612
  • HY-162128

    Histone Acetyltransferase Cancer
    Antitumor agent-130 (Compound 7b) is a p300 histone acetyltransferases (HAT) inhibitor with an IC50 of 1.51 μM. Antitumor agent-130 combinates with doxorubicin (HY-15142A) can significantly inhibit tumor growth and invasion in vitro and in vivo .
    Antitumor agent-130
  • HY-103669

    Histone Acetyltransferase Cancer
    HAT-IN-1 is an inhibitor of HAT, used in the research of cancer.
    HAT-IN-1
  • HY-146277

    Histone Acetyltransferase Cancer
    CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity .
    CBP/p300-IN-19
  • HY-146277A

    Histone Acetyltransferase Cancer
    CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity .
    CBP/p300-IN-19 hydrochloride
  • HY-149257

    JAK STAT Cancer
    HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions .
    HAT-SIL-TG-1&AT
  • HY-155024

    Parasite Infection
    HAT-IN-8 (Compound 38) is a BBB-penetrable T. brucei inhibitor (EC50: 0.18 μM). HAT-IN-8 can be used for the research of Human African trypanosomiasis .
    HAT-IN-8
  • HY-139149

    Histone Acetyltransferase Cancer
    NiCur is a potent and selective CBP histone acetyltransferase (HAT) inhibitor with an IC50 value of 0.35 μΜ. NiCur, which blocks CBP HAT activity and downregulates p53 activation upon genotoxic stress. NiCur can be used for performing mechanistic studies without affecting the expression of target proteins .
    NiCur
  • HY-143441

    Histone Acetyltransferase Cancer
    CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC50s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively .
    CBP/p300-IN-17
  • HY-143442

    Histone Acetyltransferase Cancer
    CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC50s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively .
    CBP/p300-IN-18
  • HY-143440

    Histone Acetyltransferase Cancer
    CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC50s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively .
    CBP/p300-IN-16
  • HY-147290

    Histone Acetyltransferase Cancer
    NSC 694623 is a potent histone acetyltransferase (HAT) inhibitor with an IC50 value of 15.9 μM for recombinant HAT p300/CBP-associated factor (PCAF). NSC 694623 has antiproliferative activity against certain cancer cells. NSC 694623 can be used for researching anticancer .
    NSC 694623
  • HY-138945

    Histone Acetyltransferase Cancer
    SYY-B085-1 is a histone acetyltransferase (HAT) inhibitor extracted from patent WO2019201291A1 .
    SYY-B085-1
  • HY-131035

    Histone Acetyltransferase Cancer
    Lys-CoA TFA is a selective p300 histone acetyltransferase (HAT) inhibitor (IC50=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC50=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation .
    Lys-CoA TFA
  • HY-155310

    YAP Cancer
    AF-2112 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2.
    AF-2112
  • HY-139149A

    Histone Acetyltransferase Cancer
    (E/Z)-NiCur is the active isomer of NiCur (HY-139149). (E/Z)-NiCur is a potent CBP histone acetyltransferase (HAT) inhibitor .
    (E/Z)-NiCur
  • HY-124696
    PU139
    3 Publications Verification

    Histone Acetyltransferase Cancer
    PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC50s of 8.39, 9.74, 2.49 and 5.35 μM, respectively .
    PU139
  • HY-145386

    Others Cancer
    (S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
    (S,S)-CPI-1612
  • HY-136285A

    Others Cancer
    (R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC50 of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .
    (R,R)-CPI-1612
  • HY-N2020
    Anacardic Acid
    5+ Cited Publications

    Hydroginkgolic acid; Ginkgolic Acid C15:0

    Histone Acetyltransferase Epigenetic Reader Domain Bacterial Cancer
    Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC50s of ∼8.5 μM and ∼5 μM, respectively.
    Anacardic Acid
  • HY-N2345

    Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor Inflammation/Immunology Cancer
    Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .
    Procyanidin B3
  • HY-155655

    Parasite Infection
    JC-229 is a TbRPA1 inhibitor. JC-229 targets RPA1 in Trypanosoma brucei. JC-229 can be used for the research of Human African Trypanosomiasis (HAT) .
    JC-229
  • HY-147288

    Histone Acetyltransferase Cancer
    NSC 694621 is a potent PCAF inhibitor, with an IC50 of 5.71 µM (PCAF/H31-21). NSC 694621 exhibits good activity of inhibiting the proliferation of cancer cells .
    NSC 694621
  • HY-147289

    Histone Acetyltransferase Cancer
    NSC 698600 is a potent PCAF inhibitor, with IC50 of 6.51 µM (PCAF/H31-21). NSC 698600 exhibits good activity of inhibiting the proliferation of cancer cells .
    NSC 698600
  • HY-155309

    YAP Cancer
    LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells .
    LM-41
  • HY-107455
    A-485
    Maximum Cited Publications
    53 Publications Verification

    Epigenetic Reader Domain Histone Acetyltransferase Cancer
    A-485 is a potent and selective catalytic inhibitor of p300/CBP with IC50s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively .
    A-485
  • HY-N2345R

    Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor Inflammation/Immunology Cancer
    Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .
    Procyanidin B3 (Standard)
  • HY-125084

    Parasite Infection
    NEU617 is an anti-parasite agent. NEU617 inhibits the proliferation for the HAT (human African trypanosomiasis) pathogen (EC50: 42 nM for Trypanosoma brucei, 1.8 μM for T. cruzi). NEU617 is a derivative of Lapatinib (HY-50898) .
    NEU617
  • HY-N2020R

    Histone Acetyltransferase Epigenetic Reader Domain Bacterial Cancer
    Anacardic Acid (Standard) is the analytical standard of Anacardic Acid. This product is intended for research and analytical applications. Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC50s of ~8.5 μM and ~5 μM, respectively.
    Anacardic Acid (Standard)
  • HY-123604
    TH1834
    1 Publications Verification

    Histone Acetyltransferase Apoptosis Cancer
    TH1834 is a specific Tip60 (KAT5) histone acetyltransferase (HAT) inhibitor. TH1834 induces apoptosis and increases DNA damage in breast cancer. TH1834 does not affect the activity of related histone acetyltransferase MOF. Anticancer activity .
    TH1834
  • HY-152241

    Histone Acetyltransferase Cancer
    DS-9300 is a potent, orally active, selective EP300/CBP HAT inhibitor with an IC50 value of 28 nM. DS-9300 has anticancer activity and can be used in prostate cancer disease research .
    DS-9300
  • HY-163003

    Parasite Infection
    Antitrypanosomal agent 19 (compound 10) is an orally available antitrypanosomal agent. Antitrypanosomal agent 19 effectively inhibits the growth of trypanosomatids T. b. brucei, T. b. gambiense and T. b. rhodesiense, mitigating the Human trypanosomiasis (HAT)-induced acute infectious toxicity in mice .
    Antitrypanosomal agent 19
  • HY-W013274

    Histone Acetyltransferase Apoptosis Cancer
    CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .
    CPTH2
  • HY-W013274A

    Histone Acetyltransferase Apoptosis Cancer
    CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .
    CPTH2 hydrochloride
  • HY-121089

    Others Others
    P300-IN-5 is a biological inhibitor that demonstrates potent activity against histone acetyltransferases (HAT) both in vitro and in vivo. P300-IN-5 may serve as an alternative therapeutic agent, especially in contexts requiring caution, such as during breastfeeding.
    P300-IN-5
  • HY-W015239
    KAT8-IN-1
    1 Publications Verification

    Others Inflammation/Immunology Cancer
    KAT8-IN-1 is a lysine (K) acetyltransferase 8 (KAT8) inhibitor, with IC50s of 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B), respectively. KAT8 inhibits histone acetyltransferases (HATs), and could result in disease states, such as cancer or inflammatory diseases .
    KAT8-IN-1
  • HY-N0005S

    Diferuloylmethane-d6; Natural Yellow 3-d6; Turmeric yellow-d6

    Keap1-Nrf2 Ferroptosis Autophagy Histone Acetyltransferase Epigenetic Reader Domain Mitophagy Influenza Virus Infection Metabolic Disease Inflammation/Immunology
    Curcumin-d6is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.
    Curcumin-d6
  • HY-151195

    Proteasome Parasite Infection
    20S Proteasome-IN-4 (Compound 7) is a brain-penetrant, parasite-selective, orally active 20S proteasome inhibitor with an IC50 of 6.3 nM against T. b. brucei 20S proteasome. 20S Proteasome-IN-4 can be used for the research of human African trypanosomiasis (HAT) .
    20S Proteasome-IN-4
  • HY-147261

    Histone Acetyltransferase Cancer
    B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC50 values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .
    B026
  • HY-139804

    Epigenetic Reader Domain Histone Acetyltransferase HIF/HIF Prolyl-Hydroxylase Cancer
    CTK7A is a curcumin derivative with anticancer activity by inhibiting the HAT activity of p300 and reducing the autoacetylation of p300, thereby affecting its interaction with HIF-1α. The inhibition of CTK7A leads to decreased HIF-1α accumulation and activity, which can be used for cancer treatment research .
    CTK7A
  • HY-107569
    Garcinol
    1 Publications Verification

    Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite Inflammation/Immunology Cancer
    Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50s of 0.66 µM and 7.39 µM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC50= 7 μM) and p300/CPB-associated factor (PCAF, IC50 = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .
    Garcinol
  • HY-161483

    Epigenetic Reader Domain Histone Acetyltransferase Neurological Disease Cancer
    CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). CBP and p300 are two proteins with histone acetyltransferase (HAT) activity, and CBP and p300 play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, CBP/p300 can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of CBP/p300 by binding to a specific domain of the CBP/p300 protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal CBP/p300 function .
    CBP/p300 ligand 3
  • HY-155732

    Parasite Infection
    NPD-2975 (compound 30) is an orally active antitrypanosomal agent, against Human African Trypanosomiasis (HAT). NPD-2975 has low toxicity potential against human MRC-5 lung fibroblasts, and acute mouse model of T. b. brucei infection. NPD-2975 shows acceptable metabolic stability, inhibits T. b. brucei with IC500 of 70 nM in vitro. NPD-2975 also inhibits CYP enzymes resulted in IC50 values of 0.16 and 0.42 μM against CYP1A2 and CYP2C19, respectively .
    NPD-2975
  • HY-161250

    PROTACs Cancer
    Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader, which contains a CRBN ligands Pomalidomide, a 24-atom linker with 6 PEG units and a HAT inhibitor CPI-1612. Pomalidomide-NH-PEG6-amide-C2-CPI-1612 exhibits antiproliferative effects in cells multiple myeloma cells LP1 (with a DC50 of 1.2 μM), MM1S and various cancer cell lines, especially the leukemia cells .
    Pomalidomide-NH-PEG6-amide-C2-CPI-1612

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: